Articles

Good news from HARMONY

ACADIA’s pimavanserin halts trial at interim analysis after meeting primary endpoint
Written byKelsey Kaustinen
| 3 min read

SAN DIEGO—Of the roughly eight million individuals in the United States living with dementia, research suggests that some 30 percent of those patients suffer from psychosis. Dementia-related psychosis includes that seen in Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, vascular dementia and frontotemporal dementia.

ACADIA Pharmaceuticals is advancing pimavanserin, a candidate it hopes will provide a treatment for such patients. The company recently announced that the drug met its primary endpoint in the HARMONY study, which was stopped at the pre-planned interim analysis due to having significantly reduced risk of relapse of psychosis by 2.8-fold compared to placebo. Pimavanserin also met the key secondary endpoint by significantly reducing risk of discontinuation for any reason by 2.2-fold. Top-line results from the HARMONY study were presented at the 12th Clinical Trials on Alzheimer’s Disease meeting held in December.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.